Navigation Links
Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research
Date:8/29/2014

Albany, New York (PRWEB) August 29, 2014

The global companion diagnostics market will be valued at $5.6 billion in 2019. It is expected to grow at a CAGR of 18.1% from 2013 to 2019, and was valued at $1.8 billion in 2013, according to a research report published by Transparency Market Research.

For more information regarding analysis details and ToC, please visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html.

The research report, titled “Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019”, fully explores current and future possibilities in the growing segment of companion diagnostics.

The report states that the companion diagnostics market for breast cancer was the dominant sector in 2012, in terms of revenue. The upcoming sector for the near future is lung cancer. The segment is growing at a CAGR of more than 20% between 2013 and 2019. The report cites reasons for growth as the discovery of lung cancer specific biomarkers, along with a myriad of relevant companion diagnostics.

For further inquiries, ask here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=387.

The largest market according to region in 2012 was North America, with the E.U. in following. The report said that the factors that favored the market’s growth were positive healthcare policies, a growing consumer base, increasing disposable incomes, improvements in healthcare systems, and increased awareness. The acceptance of modern medicine into mainstream sectors in the U.S. and the E.U. are the prime reasons for the growth of this market. The Asia-Pacific region and the Rest of the World regions are set to show considerable growth by the year 2019. The report cites untapped potential, increasing disposable incomes, and an improving healthcare infrastructure.

The report explains that companion diagnostics are tests which assist physicians while making decisions regarding the most efficient treatment methods, depending on responses by the patient over ongoing treatment.

Key restraints as explained by the report include regulatory restrictions, commercialization of companion diagnostics, heavy procedure costs, long phases of approval, and lack of reach towards the low income countries. Key companies in the companion diagnostics market include Quagen N.V., Abbott Laboratories, Life Technologies, Genomic Health, Inc., GE Healthcare Ltd., Roche Holdings AG, Agilent Technologies, Inc., and Agendia N.V.

The report provides exhaustive details on the companion diagnostics market by segmenting it according to indications and geography. By indications, the market is classified into breast cancer, lung cancer, melanoma, gastric cancer, colorectal cancer, and others such as HIV and thalassemia. According to geography, the reports details North America, Europe, Asia-Pacific, and Rest of the World.

Contact:
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453
Email: sales(at)transparencymarketresearch(dot)com
Web: http://www.transparencymarketresearch.com/
Blog: http://www.tmrblog.com/

Read the full story at http://www.prweb.com/releases/2014/08/prweb12125015.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Companion Diagnostics Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2019
2. Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A
3. Companion Biomarkers in Drug Development - 2013 Examines Companies That Are Actively Developing and Marketing Companion Biomarkers
4. QIAGEN Announces Third Co-Development Program for Companion Diagnostics Paired With Lillys Investigational Cancer Compounds
5. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
6. ResearchMoz: Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
7. Accelerating Drug Development Through Drug & Companion Diagnostic Co-development, New Life Science Webinar Hosted by Xtalks
8. Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests
9. MarketResearchReports.Biz: Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma And Others) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019 - New Industry Report
10. Companion Diagnostics Market is Expected to Reach USD 5.6 Billion Globally in 2019: Transparency Market Research
11. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017  MIODx announced today that ... key immunotherapy technologies from the University of California, ... method to monitor a patient for response to ... CTLA-4.  The second license extends the technology with ... likely to have an immune-related adverse event (IRAE) ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... February 23, 2017 , ... David Nolte, ... Recognition Reception at Purdue Research Park of West Lafayette, Indiana. , ... of outstanding contributions to, and success with, commercializing discoveries from Purdue research. “This ...
(Date:2/23/2017)... -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological ... Linda Marbán, Ph.D, president and chief executive officer, is scheduled ... Cowen and Company 37th Annual Health Care Conference Tuesday, ... MA 29th Annual ROTH Conference ... ET) Dana Point, CA ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
(Date:2/9/2017)... , Feb. 9, 2017 The biomass boiler ... of the biomass boiler market globally in terms of ... biomass boilers. The market for biomass boilers has been ... end-user, application, and country/region. The market based on feedstock ... forest residues, biogas & energy crops, urban residues, and ...
Breaking Biology News(10 mins):